To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
This article was originally published in PharmAsia News
Selecta Biosciences Inc. and BIND Biosciences Inc., two Boston-based -- and heretofore low-profile -- young biotechs, have raised a combined $94.5 million from a mix of equity financings and strategic alliances with one of the world's largest investment funds dedicated to nanotechnology, Rusnano, and other investors
You may also be interested in...
Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets
Biotech will combine its SVP platform technology with a SAIC-developed antigen to try to find the key to treating malaria.
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.